Recombinant activated factor VII (NovoSeven®) treatment of platelet-related bleeding disorders

Recombinant activated factor VII (rFVIIa; NovoSeven®, Novo Nordisk A/S, Bagsvaerd, Denmark), used extensively for the management of hemophilia patients with inhibitors, has also been shown to be effective in the treatment of severe bleeding episodes and for coverage of surgical procedures in patient...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood coagulation & fibrinolysis 2000-04, Vol.11 Suppl 1, p.S55-S68
Hauptverfasser:	Poon, M-C, dʼOiron, R
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Hematologic and hematopoietic diseases Medical sciences Pharmacology. Drug treatments Platelet diseases and coagulopathies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!